Pricing Log in Create free account
Reset Show charts

Graham Defensive Investor

Large, sound companies with an unbroken dividend and earnings growth, at a modest price.

Open in screener How it works

Dividend Growth

Reliable payers with room to keep paying: a decade without a cut, a covered dividend, growing earnings.

Open in screener How it works

High Insider Buying

Companies where three or more insiders bought shares in the open market in the last three months.

Open in screener How it works

Piotroski High Score

Cheap companies whose finances are improving on eight or nine of Piotroski's nine tests.

Open in screener How it works

TTM trailing twelve months Q latest quarter A latest fiscal year D daily, from the latest close

Showing the 10 largest of 21 matches.
1 filter active
Table Snapshots

  1. Eli Lilly and Company

    LLY Healthcare · Drug Manufacturers General · US

    $1,366.60 +45.8% 1Y
    Low $850.51 High $1,453.00

    Eli Lilly discovers, develops, manufactures and markets medicines for people. Founded in 1875 and headquartered in Indianapolis, it is led by Chair, President and Chief Executive Officer David Ricks.

    Market cap $1.28T
    Revenue growth (Q) +38.6%
    EPS growth (Q) +16.3%
    FCF growth (Q) +21.8%
    Revenue growth (next yr) +40.9%
    Net margin 31.9%
    ROE 86.0%
    P/E 44.3×
    Forward P/E 39.6×
    P/FCF 55.8×
    Dividend yield 0.49%
    Insider ownership 4.94%
    Insider buys / sells (12M) — $310.3M
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $28.5B $34.1B $45.0B $65.2B $86.5B
    EPS $6.90 $5.80 $11.71 $22.95 $30.81
    Free cash flow $5.7B $792.0M $3.8B $9.0B $19.7B
    Net debt $12.5B $15.4B $25.3B $33.6B $42.1B

  2. Johnson & Johnson

    JNJ Healthcare · Drug Manufacturers General · US

    $275.25 +47.2% 1Y
    Low $185.12 High $282.02

    Johnson & Johnson is a healthcare company that researches, develops, manufactures and sells prescription medicines and medical technologies. It is a holding company whose operating companies manage day-to-day operations in markets around the world.

    Market cap $655.6B
    Revenue growth (Q) +5.86%
    EPS growth (Q) −95.8%
    FCF growth (Q) −21.4%
    Revenue growth (next yr) +7.46%
    Net margin 16.2%
    ROE 20.0%
    P/E 41.7×
    Forward P/E 40.4×
    P/FCF 31.6×
    Dividend yield 1.92%
    Insider ownership 0.40%
    Insider buys / sells (12M) $0.3M $150.7M
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $80.0B $85.2B $88.8B $94.2B $99.3B
    EPS $6.73 $13.72 $5.79 $11.03 $6.60
    Free cash flow $17.7B $18.6B $20.5B $20.4B $21.0B
    Net debt $4.6B $3.0B $6.1B $19.3B $18.6B

  3. AbbVie Inc.

    ABBV Healthcare · Drug Manufacturers General · US

    $290.81 +32.8% 1Y
    Low $190.75 High $302.93

    AbbVie is a research-based biopharmaceutical company that develops, manufactures and sells medicines and therapies around the world. It was founded in 2012, is headquartered in North Chicago and is led by Chief Executive Officer Robert A. Michael.

    Market cap $509.5B
    Revenue growth (Q) +10.3%
    EPS growth (Q) +2,270.0%
    FCF growth (Q) +9.97%
    Revenue growth (next yr) +10.9%
    Net margin 15.6%
    ROE −288.7%
    P/E 50.1×
    Forward P/E 37.5×
    P/FCF 27.3×
    Dividend yield 2.38%
    Insider ownership 0.00%
    Insider buys / sells (12M) — $18.9M
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $58.1B $54.3B $56.3B $61.2B $66.0B
    EPS $6.63 $2.72 $2.39 $2.36 $5.81
    Free cash flow $24.2B $22.1B $17.8B $17.8B $18.9B
    Net debt $54.0B $46.6B $61.6B $62.2B $70.1B

  4. Merck & Co., Inc.

    MRK Healthcare · Drug Manufacturers General · US

    $146.65 +71.0% 1Y
    Low $85.80 High $156.92

    Merck & Co. is a global health care company that sells prescription medicines, vaccines and animal health products. Founded in 1891, it is headquartered in Rahway and led by Chairman, President and Chief Executive Officer Robert M. Davis.

    Market cap $362.5B
    Revenue growth (Q) +4.68%
    EPS growth (Q) −12.1%
    FCF growth (Q) +77.0%
    Revenue growth (next yr) +3.43%
    Net margin 3.64%
    ROE 5.07%
    P/E 151×
    Forward P/E 97.2×
    P/FCF 24.5×
    Dividend yield 2.32%
    Insider ownership 0.32%
    Insider buys / sells (12M) — $71.3M
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $59.3B $60.1B $64.2B $65.0B $67.4B
    EPS $5.71 $0.14 $6.74 $7.28 $0.97
    Free cash flow $14.7B $9.1B $18.1B $12.4B $14.7B
    Net debt $15.6B $26.6B $20.8B $32.2B $40.0B

  5. Novartis AG

    NVS Healthcare · Drug Manufacturers General · CH

    $162.31 +28.2% 1Y
    Low $123.24 High $170.46

    Novartis AG, headquartered in Basel, Switzerland, is one of the world’s leading pharmaceutical companies. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two Swiss companies with rich histories in the pharmaceutical and chemical industries.

    Market cap $296.4B
    Revenue growth (Q) +4.67%
    EPS growth (Q) −68.9%
    FCF growth (Q) −17.8%
    Revenue growth (next yr) +1.25%
    Net margin 17.5%
    ROE 24.4%
    P/E 30.9×
    Forward P/E 23.2×
    P/FCF 21.8×
    Dividend yield 2.92%
    Insider ownership 3.48%
    Insider buys / sells (12M) — —
    Reported FY2022 FY2023 FY2024 FY2025 TTM
    Revenue $43.5B $46.7B $51.7B $56.7B $57.4B
    EPS $3.17 $7.15 $5.87 $7.15 $5.24
    Free cash flow $12.3B $13.9B $14.0B $15.4B $14.1B
    Net debt $7.2B $10.2B $16.1B $21.9B $37.4B